Paulina Górska

Paulina Górska

Auto-generated profile, based on publicly available information

Paulina Górska

Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Future Microbiology
Verified
Journal Article
Closed access
MPMarta Prygiel
Marta Prygiel
EMEwa Mosiej
Ewa Mosiej
PGPaulina Górska
Paulina Górska
AZAleksandra Anna Zasada
Aleksandra Anna Zasada
The diphtheria–tetanus–pertussis (DTP) vaccine can prevent diphtheria, tetanus and pertussis. The component antigens of the DTP vaccine had long been monovalent vaccines. The pertussis vaccine was ...

23 August 2023 in Viruses
Verified
Journal Article
Open access
PDF file
AZAleksandra Anna Zasada
Aleksandra Anna Zasada
ADAniela Darlińska
Aniela Darlińska
AWAldona Wiatrzyk
Aldona Wiatrzyk
KWKatarzyna Woźnica
Katarzyna Woźnica
KFKamila Formińska
Kamila Formińska
PGPaulina Górska
Paulina Górska
The outbreak of COVID-19 started in December 2019 and spread rapidly all over the world. It became clear that the development of an effective vaccine was the only way to stop the pandemic. It was the first time in the history of infectious diseases that the process of the development of a new vaccine was conducted on such a large scale and accelerated so rapidly. At the end of 2020, the first COVID-19 vaccines were approved for marketing. At the end of March 2023, over three years after the outbreak of the COVID-19 pandemic, 199 vaccines were in pre-clinical development and 183 in clinical development. The candidate vaccines in the clinical phase are based on the following platforms: protein subunit, DNA, RNA, non-replication viral vector, replicating viral vector, inactivated virus, virus-like particles, live attenuated virus, replicating viral vector combined with an antigen-presenting cell, non-replication viral vector combined with an antigen-presenting cell, and bacterial antigen-spore expression vector. Some of the new vaccine platforms have been approved for the first time for human application. This review presents COVID-19 vaccines currently available in the world, procedures for assurance of the quality and safety of the vaccines, the vaccinated population, as well as future perspectives for the new vaccine platforms in drug and therapy development for infectious and non-infectious diseases.


30 December 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
WJWiesława Janaszek-Seydlitz
Wiesława Janaszek-Seydlitz
MPMarta Prygiel
Marta Prygiel
BBBożena Bucholc
Bożena Bucholc
AWAldona Wiatrzyk
Aldona Wiatrzyk
UCUrszula Czajka
Urszula Czajka
USUrszula Soliwoda
Urszula Soliwoda
Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients present non-muscle invasive bladder cancer (NMIBC). Standard primary treatment for NIMBC is transurethral resection (TUR) followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. BCG has been accepted as the most effective agent in clinical use against NMIBC. Various BCG substrains are used worldwide for bladder cancer immunotherapy although the impact of used BCG substrain on BCG antitumor capacity is a little investigated. The aim of this study was to compare the antitumor capacity and the ability to trigger cytokines production of three BCG substrains by stimulation of the local innate immunity in vitro. The human bladder cancer cell line T24 was co-cultured with each of the BCG substrains: Moreau, Tice and RIVM alone or with BCG pretreated DCs (dendric cells) and allogenic PBMCs derived from the same donor. The inhibition of T24 cell growth was evaluated by 3H-thymidine incorporation. Production of Th1 cytokines (IFN-γ, TNF-α, IL-12) and Th2 cytokines (IL-10, IL-4) was measured in cultures of BCG-activated PBMCs by ELISA test. An approximately two-fold inhibition of T24 cell proliferation was observed as a direct cytotoxic effect of tested BCG substrains on T24 cells. However, BCG inhibited the growth of tumor cells mainly by activating the effector cells of innate immunity. About a 10-fold inhibition of T24 cell proliferation was observed when T24 cells were co-cultured with allogenic BCG pretreated DCs and PBMCs derived from the same donor. The PBMCs activated by compared live BCG substrains secreted large amounts of TNF-α and IFN-γ cytokines. Tested BCG substrains had little direct inhibitory effect on T24 cell proliferation. Moreau evolutionarily early BCG substrain showed similar strong, indirect antitumor effects as evolutionarily late BCG substrains Tice and RIVM.

1 January 2011
Verified
Journal Article
Closed access
BBBozenna Bucholc
Bozenna Bucholc
PGPaulina Górska
Paulina Górska
WJWiesława Janaszek-Seydlitz
Wiesława Janaszek-Seydlitz

1 January 2022 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
PGPaulina Górska
Paulina Górska
MGMałgorzata Główka
Małgorzata Główka
KWKatarzyna Woźnica
Katarzyna Woźnica
AZAleksandra Anna Zasada
Aleksandra Anna Zasada
Górska P, et al. Clin Exp Vaccine Res. 2022 May;11(2):155-162. https://doi.org/10.7774/cevr.2022.11.2.155